Pharma-Tech

Pharma-Tech is an Egyptian joint stock company established in 2006.Here at Pharma-Tech we inspire for good health and better quality of life by offering a wide range of carefully selected products that will help millions of people live their lives better and healthier.we aim to touch people lives not just in Egypt but also in Middle East, Africa, and Europe. We will be involved in different therapeutic areas to help challenge the most feared diseases of our time like Osteoporosis, hyperprolactinemia, and hepatitis. At pharma-Tech we believe in the concept of “pain free hospitals” that’s why we will be offering different products in pain management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

news image

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More

PHARMACY MARKET

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

news image

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More

BUSINESS INSIGHTS

TENDONOVA WINS FDA CLEARANCE FOR ITS NEW MICROINVASIVE OCELOT SURGICAL TOOL

TendoNova | March 24, 2022

news image

TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510 clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue. The FDA found the Ocelot TDS 1000 substantially equivalent to the Tenex TX1 which is routinely used for percutaneous tenotomy in orthopedics, sports medicine, pain management, and podiatry. The Ocelot System's form factor and price point make it an exciting ...

Read More

PHARMACY MARKET

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

news image

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More
news image

PHARMACY MARKET

EYEPOINT PHARMACEUTICALS ANNOUNCES CLOSING OF $115.4 MILLION PUBLIC OFFERING

EyePoint Pharmaceuticals | November 20, 2021

EyePoint Pharmaceuticals, Inc. a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 1,095,000 shares of common stock, and pre-funded warrants to purchase up to an aggregate of 3,272,727 s...

Read More
news image

PHARMACY MARKET

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More
news image

BUSINESS INSIGHTS

TENDONOVA WINS FDA CLEARANCE FOR ITS NEW MICROINVASIVE OCELOT SURGICAL TOOL

TendoNova | March 24, 2022

TendoNova, an emerging leader in microinvasive sports medicine procedures, is pleased to announce the FDA 510 clearance of its new Ocelot surgical tool, which uses an innovative technology for fragmentation or debridement of soft tissue. The FDA found the Ocelot TDS 1000 substantially equivalent to the Tenex TX1 which is routinely used for percutaneous tenotomy in orthopedics, sports medicine, pain management, and podiatry. The Ocelot System's form factor and price point make it an exciting ...

Read More
news image

PHARMACY MARKET

ATARA BIOTHERAPEUTICS AND PIERRE FABRE ENTER STRATEGIC COLLABORATION TO COMMERCIALIZE TABELECLEUCEL (TAB-CEL®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and...

Read More